4/A//SEC Filing
AVADEL PHARMACEUTICALS PLC 4/A
Accession 0001140361-17-009161
$AVDLCIK 0001012477operating
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 4:37 PM ET
Size
13.9 KB
Accession
0001140361-17-009161
Insider Transaction Report
Form 4/AAmended
NAVARRE CHRISTOPHE
Director
Transactions
- Award
Warrants (right to buy)
2017-01-03+54,026→ 54,026 totalExercise: $13.59From: 2017-08-10Exp: 2020-08-17→ ADSs (54,026 underlying) - Award
Warrants (right to buy)
2017-01-03+46,000→ 46,000 totalExercise: $14.54From: 2015-06-24Exp: 2018-06-24→ ADSs (46,000 underlying) - Award
Warrants (right to buy)
2017-01-03+54,026→ 54,026 totalExercise: $21.67From: 2016-06-26Exp: 2019-06-26→ ADSs (54,026 underlying)
Footnotes (6)
- [F1]Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 46,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS.
- [F2]On 12/31/16, Flamel Technologies S.A. ("Flamel") merged with and into Avadel Pharmaceuticals plc ("Avadel"). As a result of the Merger, Flamel's outstanding ordinary shares were cancelled and exchanged on a 1-for-1 basis for newly issued ordinary shares of Avadel, and all outstanding American Depositary Shares (ADSs) representing Flamel ordinary shares were cancelled and exchanged on a 1-for-1 basis for ADSs representing Avadel ordinary shares. The reporting person filed a Form 4 solely to report dispositions of Flamel securities as a result of the Merger, and filed a Form 3 to reflect the reporting person's new status as a director and/or executive officer of Avadel. This Form 4 reports the reporting person's acquisition of the same number and type of securities of Avadel in the Merger. The reporting person made no market sales or purchases in connection with the dispositions reported in the Form 4 referenced above or the acquisitions reported in this Form 4.
- [F3]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- [F4]Flamel Ordinary Shares and Flamel ADSs were exchanged in the Merger for an equal number of Avadel Ordinary Shares and Avadel ADSs (as applicable), respectively.
- [F5]Warrants were granted 06/26/2015 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 54,026 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS. Warrants as to all 54,026 ADSs vest on 06/26/2016.
- [F6]Warrants were granted 08/10/2016 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 54,026 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 54,026 ADSs vest on 08/10/2017.
Documents
Issuer
AVADEL PHARMACEUTICALS PLC
CIK 0001012477
Entity typeoperating
Related Parties
1- filerCIK 0001012477
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 4:37 PM ET
- Size
- 13.9 KB